These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9785508)

  • 21. Clinical, Virological and Immunological Responses after Experimental Infection with African Horse Sickness Virus Serotype 9 in Immunologically Naïve and Vaccinated Horses.
    Durán-Ferrer M; Villalba R; Fernández-Pacheco P; Tena-Tomás C; Jiménez-Clavero MÁ; Bouzada JA; Ruano MJ; Fernández-Pinero J; Arias M; Castillo-Olivares J; Agüero M
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA.
    Wade-Evans AM; Woolhouse T; O'Hara R; Hamblin C
    J Virol Methods; 1993 Dec; 45(2):179-88. PubMed ID: 8113344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
    Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
    Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
    Chiam R; Sharp E; Maan S; Rao S; Mertens P; Blacklaws B; Davis-Poynter N; Wood J; Castillo-Olivares J
    PLoS One; 2009 Jun; 4(6):e5997. PubMed ID: 19543394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the three-dimensional structure of the African horse sickness virus VP7 trimer by homology modelling.
    Bekker S; Burger P; van Staden V
    Virus Res; 2017 Mar; 232():80-95. PubMed ID: 28167267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of a Soluble African Horse Sickness Virus VP7 Protein Capable of Forming Core-like Particles.
    Bekker S; Huismans H; van Staden V
    Viruses; 2022 Jul; 14(8):. PubMed ID: 35893692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
    Rutkowska DA; Mokoena NB; Tsekoa TL; Dibakwane VS; O'Kennedy MM
    BMC Vet Res; 2019 Dec; 15(1):432. PubMed ID: 31796116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral susceptibility of South African Culicoides species to live-attenuated serotype-specific vaccine strains of African horse sickness virus (AHSV).
    Paweska JT; Prinsloo S; Venter GJ
    Med Vet Entomol; 2003 Dec; 17(4):436-47. PubMed ID: 14651659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR
    O'Kennedy MM; Coetzee P; Koekemoer O; du Plessis L; Lourens CW; Kwezi L; du Preez I; Mamputha S; Mokoena NB; Rutkowska DA; Verschoor JA; Lemmer Y
    Vaccine; 2022 Aug; 40(35):5160-5169. PubMed ID: 35902279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Microsphere-based Immunoassay for Serological Detection of African Horse Sickness Virus and Comparison with Other Diagnostic Techniques.
    Sánchez-Matamoros A; Beck C; Kukielka D; Lecollinet S; Blaise-Boisseau S; Garnier A; Rueda P; Zientara S; Sánchez-Vizcaíno JM
    Transbound Emerg Dis; 2016 Dec; 63(6):e270-e277. PubMed ID: 25693720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plant expression systems as an economical alternative for the production of iELISA coating antigen AHSV VP7.
    Fearon SH; Dennis SJ; Hitzeroth II; Rybicki EP; Meyers AE
    N Biotechnol; 2022 May; 68():48-56. PubMed ID: 35114407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
    Crafford JE; Lourens CW; Gardner IA; Maclachlan NJ; Guthrie AJ
    Equine Vet J; 2013 Sep; 45(5):604-7. PubMed ID: 23294121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.
    Faber FE; van Kleef M; Tshilwane SI; Pretorius A
    Virus Res; 2016 Jul; 220():12-20. PubMed ID: 27063332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
    Stone-Marschat MA; Moss SR; Burrage TG; Barber ML; Roy P; Laegreid WW
    Virology; 1996 Jun; 220(1):219-22. PubMed ID: 8659117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
    van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
    Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serological and virological responses in mules and donkeys following inoculation with African horse sickness virus serotype 4.
    el Hasnaoui H; el Harrak M; Zientara S; Laviada M; Hamblin C
    Arch Virol Suppl; 1998; 14():29-36. PubMed ID: 9785493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent.
    Chuma T; Le Blois H; Sánchez-Vizcaíno JM; Diaz-Laviada M; Roy P
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():925-31. PubMed ID: 1378881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.
    Kanai Y; van Rijn PA; Maris-Veldhuis M; Kaname Y; Athmaram TN; Roy P
    Vaccine; 2014 Sep; 32(39):4932-7. PubMed ID: 25045805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.